Get started
Aclaris Therapeutics, Inc.Aclaris Therapeutics, Inc.Aclaris Therapeutics, Inc.

Aclaris Therapeutics, Inc.

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals

ACRS trade ideas

ACRS Aclaris Therapeutics Potential BuyoutACRS Aclaris Therapeutics has 3 clinical trials releasing topline data this year and sufficient cash to fund their operations through the end of 2025. ACRS is in Piper Sandler`s potential 12 biotech takeovers in 2023. ACRS reached 52 week low today: $5.05. Analysts Price Targets: $21 The Goldman Sachs Group $29 BTIG Research $38 Cantor Fitzgerald $43 HC Wainwright Considering the above, I think ACRS might be an easy +3X! Looking forward to read your opinion about it.
NASDAQ:ACRSLong
by TopgOptions
3
ACRS Breakout Stock Sell AlertBREAKOUT STOCK SELL ALERT $ACRS - Aclaris Therapeutics, Inc. - Common Stock Initial Alert Price: $3.46 Price High: $19.80 % Gains/Losses: 472.25% (+450% More Than Expected) ACRS topped out at $19.80 in Today's Trading Session providing a 454% Return on our Initial Trade Alert from Dec. 1st when the stock once only $3.46. This comes after the company announced that its ATI-450 drug candidate demonstrated "durable clinical activity" in a phase 2a trial in patients with moderate to severe rheumatoid arthritis over a 12-week period. We are seeing signals of Profit-Taking/Consolidation from today's run, so we suggest staying on high-alert watching this stock moving forward, as we will be adding it to our watchlist for another potential re-entry after consolidation completes. #Breakout #Stocks #Trading #Investing #Alerts #StockMarket #Daily #News #Today
NASDAQ:ACRS
by MyMIWallet
7
ACRS Breakout Stock Alert UpdateBREAKOUT STOCK ALERT UPDATE $ACRS - Aclaris Therapeutics, Inc. - Common Stock Initial Alert Price: $3.46 Price High: $7.95 % Gains/Losses: 129.77% (+107.77% More Than Expected) Potential Stop Loss: $7.55 ACRS hit $7.95 in this morning's Premarket Session hitting a 52-Week High. The stock is currently consolidating from the run it's been on since Dec. 11th, so we are watching this closely to see where it finds support again moving forward. At this time, we're keeping this trade alert opened. #Breakout #Stocks #Trading #Investing #Alerts #StockMarket #Daily #News #Today Follow for more trade alerts and information & register your account for Instant Alerts by clicking the link in our signature.
NASDAQ:ACRSLong
by MyMIWallet
ACRS Breakout Stock Alert UpdateBREAKOUT STOCK ALERT UPDATE $ACRS - Aclaris Therapeutics, Inc. - Common Stock Initial Alert Price: $3.46 Price High: $7.09 % Gains/Losses: 104.91% (+82.91% More Than Expected) Potential Stop Loss: $6.74 ACRS just cleared 104.91% on our initial trade alert in today's trading session. We would suggest selling half of positions here, and placing a trailing stop loss on the rest of the position to safeguard losing any current profits, but still allowing the stock to produce more profits. We haven't seen any press releases to cause the catalyst and it seems that it was pure momentum in the stock, especially after hitting it's 52-Wk Highs. We will be on the lookout for consolidation moving forward, but this isn't currently showing signs of losing steam. #Breakout #Stocks #Trading #Investing #Alerts #StockMarket #Daily #News #Today Follow for more trade alerts and information & egister your account for Instant Alerts by clicking the link in our signature.
NASDAQ:ACRSLong
by MyMIWallet
ACRS Breakout Stock Alert UpdateBREAKOUT STOCK ALERT UPDATE $ACRS - Aclaris Therapeutics, Inc. - Common Stock Initial Alert Price: $3.46 Price High: $6.60 % Gains/Losses: 90.75% (90.53% More Than Expected) Stop Loss Limit: $6.27 ACRS is currently completing consolidation from it's most recent Oct. 12th 5.02 breakout after announcing beginning of Phase 2a Clinical Trials. The stock has some great headway for growth and we look to see a nice return here for current/future investors. #Breakout #Stocks #Trading #Investing #Alerts #StockMarket #Daily #News #Today Follow for more trade alerts and information & egister your account for Instant Alerts by clicking the link in our signature.
NASDAQ:ACRSLong
by MyMIWallet
ACRS Brekout Stock Alert UpdateBREAKOUT STOCK ALERT UPDATE $ACRS - Aclaris Therapeutics, Inc. - Common Stock Initial Alert Price: $3.46 Price High: $4.18 % Gains/Losses: 20.81% (20.59% More Than Expected) Stop Loss Limit: $3.97 ACRS is currently completing consolidation from it's most recent Oct. 12th 5.02 breakout after announcing beginning of Phase 2a Clinical Trials. The stock has some great headway for growth and we look to see a nice return here for current/future investors. #Breakout #Stocks #Trading #Investing #Alerts #StockMarket #Daily #News #Today Follow for more trade alerts and information & egister your account for Instant Alerts by clicking the link in our signature.
NASDAQ:ACRSLong
by MyMIWallet
Two Stocks for Positive Bull Run ContinuationI think that ACRS as it stands is a Covid19 play and could be the next CAPR with its drug discovery targets. Positive sentiment will keeping coming up. I also think that CLPS as an IT company will still have some positive sentiment and support correlations, at least on Monday. If I were you, I would likely be long pre or open market hours entry. That being said, everything I say is on an opinion based basis. Please do your own due diligence and proceed with caution. Invest at your own risk.
NASDAQ:ACRSLong
by gamer456148
$acrs Aclaris Therapeutics level to watch Aclaris Therapeutics (NASDAQ:ACRS) is up 19.9% after hours following positive results from its Phase 1 trial of ATI-450, an investigational oral MK2 inhibitor. The trial covered single ascending dose and multiple ascending dose approaches. The treatment was well tolerated at all doses and resulted in marked inhibition of TNFa, IL1ß, IL8, and IL6, the company says. “We believe these data support the progression of ATI-450 into Phase 2 clinical development,” says Chief Medical Officer Dr. David Gordon. The company plans to initiate a Phase 2 trial in subjects with rheumatoid arthritis in the first half of the year. Cource seeking alpha Aclaris Therapeutics, Inc. operates as a dermatologist-led biopharmaceutical company, which engages in identifying, developing, and commercializing novel drugs to address the needs in medical and aesthetic dermatology and immunology. It operates through Dermatology Therapeutics and Contract Research segments. The Dermatology Therapeutics segment focuses in identifying, developing, and commercializing innovative and differentiated therapies to address significant unmet needs in medical and aesthetic dermatology. The Contract Research segment provides laboratory services under contract research arrangements to pharmaceutical and biotech companies. The company was founded by Neal S. Walker, Frank Ruffo, Kamil Ali-Jackson, Christopher V. Powala, and Stuart D. Shanler in July 2012 and is headquartered in Malvern, PA.
NASDAQ:ACRS
by DEXWireNews
BIG Phase Data Out ACRS BUTBut keep in mind this is Phase 1 for ACRS . Still a long road ahead. I'm not taking anything away from the company at all. Congrats on the win and I hope the momo continues but I've seen so many of these go parabolic. Needless to say, could be something to watch over the next few days "This time around, Aclaris Therapeutics Inc. has caught attention after announcing positive phase trial results. In the company’s Phase 1 Single and Multiple Ascending Dose Trial of its ATI-450 showed favorable results from dosing and tolerability." SOUCE: 4 Penny Stocks To Buy Or Sell Ahead Of Employment Data?
NASDAQ:ACRS
by PennyStocks101